MARLBOROUGH, Mass., June 15, 2022 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement with Synergy Innovation Co., Ltd, to purchase its majority stake (approximately 64 percent) of M.I.Tech Co., Ltd, (“M.I.Tech”) a publicly traded […]
Tag: Boston Scientific
Boston Scientific Receives FDA Clearance for the EMBOLD™ Fibered Detachable Coil
MARLBOROUGH, Mass., April 28, 2022 – Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the EMBOLD™ Fibered Detachable Coil, which is indicated to obstruct or reduce the rate of blood flow in the peripheral […]
BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FIRST QUARTER 2022
MARLBOROUGH, Mass., April 27, 2022 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.026 billion during the first quarter of 2022, growing 10.0 percent on a reported basis, 12.6 percent on an operational1 basis and 9.7 percent on an organic2 basis, all compared to […]
Late-Breaking Study Results Reinforce Positive Real-World Outcomes with the WATCHMAN FLX™ LAAC Device
MARLBOROUGH, Mass., Feb. 28, 2022 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced positive results from a new analysis assessing real-world outcomes with the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device. Presented during a late-breaking trial session at the Cardiovascular Research Technologies […]
Boston Scientific Closes Acquisition of Baylis Medical Company Inc.
MARLBOROUGH, Mass., Feb. 15, 2022 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Baylis Medical Company Inc., a company that offers advanced transseptal access solutions as well as guidewires, sheaths and dilators used to support catheter-based left-heart procedures. “The […]
Boston Scientific Initiates Trial to Evaluate Industry’s First Modular CRM System
Trial studying communication between cardiac rhythm management devices aims to expand treatment options for patients who require an ICD MARLBOROUGH, Mass., Dec. 2, 2021 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) has initiated the MODULAR ATP clinical trial to evaluate the safety, performance […]
Boston Scientific Announces Results For Third Quarter 2021
MARLBOROUGH, Mass., Oct. 27, 2021 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.932 billion during the third quarter of 2021, growing 10.3 percent on a reported basis, 9.7 percent on an operational1 basis and 10.6 percent on an organic2 basis, all compared […]
Boston Scientific Eluvia™ Drug-Eluting Vascular Stent System Exhibits Superiority Compared to Bare Metal Stents
Late-breaking data demonstrate superior rates of primary patency and statistically significant sustained clinical improvement LAS VEGAS and MARLBOROUGH, Mass., Oct. 6, 2021 /PRNewswire/ — Today, Boston Scientific Corporation (NYSE: BSX) announced positive data for the Eluvia™ Drug-Eluting Vascular Stent System (Eluvia stent) during a late-breaking […]
Positive Late-breaking Clinical Trial Data for the EkoSonic™ Endovascular System Presented at VIVA21
Analysis found no intracerebral hemorrhages, low major bleeding rates; registry represents largest data set in interventional treatment of pulmonary embolism LAS VEGAS and MARLBOROUGH, Mass., Oct. 5, 2021 /PRNewswire/ — Today, Boston Scientific (NYSE: BSX) announced positive results for the EkoSonic™ Endovascular System (EKOS system) during […]
Boston Scientific Corporation to acquire Baylis Medical Company
Baylis Medical Technologies to increase investment in radiology and neurosurgery business in Canada MISSISSAUGA, Ont. (October 6, 2021) – Baylis Medical Company Inc. is pleased to announce it has reached an agreement to sell its cardiology business to Boston Scientific […]